Michael Khalil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4957321/publications.pdf

Version: 2024-02-01

63 4,272 25 60 papers citations h-index g-index

64 64 64 64 6642

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Neurofilament light chain: a new marker for neuronal decay in the anterior chamber fluid of patients with glaucoma. British Journal of Ophthalmology, 2023, 107, 1432-1437.	2.1	4
2	Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. Multiple Sclerosis Journal, 2022, 28, 61-70.	1.4	20
3	Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103353.	0.9	9
4	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
5	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. Neuroradiology, 2022, 64, 1383-1390.	1.1	2
6	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	3.1	82
7	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	4.9	210
8	Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria. Medicina (Lithuania), 2022, 58, 433.	0.8	5
9	Incidence of Developmental Venous Anomalies in Patients With Multiple Sclerosis: A 3 Tesla MRI Study. Frontiers in Neurology, 2022, 13, 824347.	1.1	0
10	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. Annals of Neurology, 2022, 91, 814-820.	2.8	7
11	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
12	Periventricular magnetisation transfer abnormalities in early multiple sclerosis. NeuroImage: Clinical, 2022, 34, 103012.	1.4	5
13	Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 954-963.	1.4	9
14	Serum neurofilament level increases after ascent to 4559Âm but is not related to acute mountain sickness. European Journal of Neurology, 2021, 28, 1004-1008.	1.7	4
15	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	19
16	MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study. Journal of Neurology, 2021, 268, 3808-3816.	1.8	8
17	Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis. Biomolecules, 2021, 11, 1264.	1.8	3
18	Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients. Frontiers in Immunology, 2021, 12, 718895.	2.2	3

#	Article	IF	CITATIONS
19	Factors influencing serum neurofilament light chain levels in normal aging. Aging, 2021, 13, 25729-25738.	1.4	38
20	CD19+lgD+CD27- NaÃ-ve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients. Frontiers in Immunology, 2021, 12, 803742.	2.2	27
21	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	1.4	52
22	Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1682-1690.	1.4	25
23	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
24	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications, 2020, 11, 812.	5.8	316
25	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	3.9	31
26	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1535-1538.	1.4	5
27	Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1669-1677.	2.4	27
28	Morphological MRI phenotypes of multiple sclerosis differ in resting-state brain function. Scientific Reports, 2019, 9, 16221.	1.6	8
29	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
30	Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988598.	0.5	6
31	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	1.1	22
32	Month-of-birth-effect in multiple sclerosis in Austria. Multiple Sclerosis Journal, 2019, 25, 1870-1877.	1.4	6
33	The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 48-54.	1.4	16
34	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881953.	0.5	19
35	The effect of disease modifying therapies on CD62L expression in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731880081.	0.5	4
36	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177

3

#	Article	IF	CITATIONS
37	Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?. Multiple Sclerosis Journal, 2018, 24, 1270-1271.	1.4	11
38	Prognostic value of free light chains lambda and kappa in early multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1496-1505.	1.4	34
39	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
40	Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology, 2017, 89, 2108-2114.	1.5	139
41	Mucosal biopsy shows immunologic changes of the colon in patients with early MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e362.	3.1	7
42	Comment on the letter to the editor entitled "Brain iron deposition in patients with white matter hyperintensities of presumed vascular origin―by D. Zhou. Neurobiology of Aging, 2017, 53, 198.	1.5	0
43	Multimodal assessment of white matter tracts in amyotrophic lateral sclerosis. PLoS ONE, 2017, 12, e0178371.	1.1	12
44	No evidence for increased brain iron deposition in patients with ischemic white matter disease. Neurobiology of Aging, 2016, 45, 61-63.	1.5	17
45	Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroinflammation, 2016, 13, 176.	3.1	14
46	CSF neurofilament light. Neurology, 2016, 87, 1068-1069.	1.5	16
47	Poor short-term outcome in patients with ischaemic stroke and active cancer. Journal of Neurology, 2016, 263, 150-156.	1.8	79
48	Periventricular lesions correlate with cortical thinning in multiple sclerosis. Annals of Neurology, 2015, 78, 530-539.	2.8	29
49	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
50	Predictive value of different conventional and non-conventional MRI-parameters for specific domains of cognitive function in multiple sclerosis. NeuroImage: Clinical, 2015, 7, 715-720.	1.4	27
51	Dynamics of brain iron levels in multiple sclerosis. Neurology, 2015, 84, 2396-2402.	1.5	61
52	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
53	IV thrombolysis in patients with ischemic stroke and alcohol abuse. Neurology, 2015, 85, 1592-1597.	1.5	13
54	Higher Education Moderates the Effect of T2 Lesion Load and Third Ventricle Width on Cognition in Multiple Sclerosis. PLoS ONE, 2014, 9, e87567.	1.1	46

#	Article	lF	CITATIONS
55	Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e1.	3.1	2
56	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 1692-1698.	1.4	47
57	Quantitative Susceptibility Mapping in Multiple Sclerosis. Radiology, 2013, 267, 551-559.	3.6	216
58	Idiopathic hypertrophic cranial pachymeningitis: a rare but treatable cause of headache and facial pain. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 354-355.	0.9	5
59	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	1.4	133
60	Neurofilaments as biomarkers in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 552-556.	1.4	195
61	Iron and Neurodegeneration in Multiple Sclerosis. Multiple Sclerosis International, 2011, 2011, 1-6.	0.4	40
62	MRI assessment of iron deposition in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2011, 34, 13-21.	1.9	84
63	Epstein-Barr virus encephalitis presenting with a tumor-like lesion in an immunosuppressed transplant recipient. Journal of NeuroVirology, 2008, 14, 574-578.	1.0	18